PROLONGEVITY | EVIDENCE-BASED COMMENTARY GLP-1 SAFETY | 6 AUGUST 2026 Can Mounjaro, Wegovy or Ozempic Kill You? What today's 'GLP-1 deaths' headlines really mean - and how a lifestyle-first, lowest-effective-dose approach changes the conversation By Graham Phillips FRPharmS, The Pharmacist Who Gave Up Drugs If you use Mounjaro, Wegovy or Ozempic, you may have seen today's frightening headlines reporting deaths linked to GLP-1 medicines. Some reports now refer to more than 200 deaths. So should you be worried? Should you stop your injection? And, bluntly: could it kill you? THE 30-SECOND ANSWER Yes, GLP-1 and GIP/GLP-1 medicines can cause serious adverse effects and, very rarely, those complications can be fatal. But a death reported to the MHRA Yellow Card scheme is not the same thing as a death proven to have been caused by the drug. We cannot use Yellow Card totals to calculate your personal risk of dying. And in a large randomised trial of Wegovy in a high-risk population, semaglutide was associated with fewer deaths than placebo. The sensible response is neither panic nor complacency: use these medicines only when the likely benefit justifies the risk, with proper supervision and no more drug than you actually need. What are today's headlines actually saying? The Times reported more than 100,000 suspected adverse reactions for tirzepatide (Mounjaro), around 44,000 for Wegovy and just over 3,000 for Saxenda. In terms of fatalities the Times reported 153 suspected deaths across Mounjaro, Wegovy and Saxenda (98, 37 and 18 respectively) based on MHRA Yellow Card data. Other UK coverage published the following day in The Sun reported a higher total of 216 (120, 59 and 37 respectively). The reason for the discrepancy between the two reported extracts is not clear from the published articles. Medicine Adverse reactions Serious Fatal outcomes Mounjaro (tirzepatide) 100,810 10,434 98 Wegovy (semaglutide) 44,073 4,892 37 Saxenda (liraglutide) 3,021 734 18 Source: figures reported by The Times, 5-6 August 2026. These are suspected adverse-reaction/fatal-outcome reports, not adjudicated drug-caused deaths; a single patient may generate more than one reaction report.